Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Open Access
- 19 October 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 225 (1) , 19-29
Abstract
Statins may be protective in severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection. The aim of the current study was to evaluate the effect of in-hospital statin use on 28-day mortality rates and intensive care unit (ICU) admission among patients with SARS-CoV-2, stratified into 4 groups: those who used statins before hospitalization (treatment continued or discontinued in the hospital) and those who did not (treatment newly initiated in the hospital or never initiated). In a cohort study of 1179 patients with SARS-CoV-2, record review was used to assess demographics, laboratory measurements, comorbid conditions, and time from admission to death, ICU admission, or discharge. Using marginal structural Cox models, we estimated hazard ratios (HRs) for death and ICU admission. Among 1179 patients, 676 (57%) were male, 443 (37%) were >65 years old, and 493 (46%) had a body mass index ≥30 (calculated as weight in kilograms divided by height in meters squared). Inpatient statin use reduced the hazard of death (HR, 0.566; P=.008). This association held among patients who did and those who did not use statins before hospitalization (HR, 0.270 [P=.003] and 0.493 [P=.04], respectively). Statin use was associated with improved time to death for patients aged >65 years but not for those ≤65 years old. Statin use during hospitalization for SARS-CoV-2 infection was associated with reduced 28-day mortality rates. Well-designed randomized control trials are needed to better define this relationship.Keywords
All Related Versions
Funding Information
- National Institutes of Health (ES007142)
- National Institute of General Medical Sciences (R01 GM127862)
This publication has 46 references indexed in Scilit:
- Rosuvastatin for Sepsis-Associated Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2014
- A marginal structural model for multiple-outcome survival data:assessing the impact of injection drug use on several causes of death in the Canadian Co-infection CohortStatistics in Medicine, 2013
- A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe SepsisAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)Critical Care, 2012
- Association Between Use of Statins and Mortality Among Patients Hospitalized With Laboratory-Confirmed Influenza Virus Infections: A Multistate StudyThe Journal of Infectious Diseases, 2011
- Statins for acute coronary syndrome2011
- Statins in community acquired pneumonia: Evidence from experimental and clinical studiesRespiratory Medicine, 2010
- Statins for sepsis: a critical and updated reviewClinical Microbiology and Infection, 2009
- Lipid rafts are involved in SARS-CoV entry into Vero E6 cellsBiochemical and Biophysical Research Communications, 2008
- Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of StatinsChest, 2007